FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Shattuck Labs, Inc. Stock AnalysisComprehensive stock analysis for Shattuck Labs, Inc. (STTK) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSTTK
STTK
Shattuck Labs, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
STTK
Home🔹Stocks🔹Shattuck Labs, Inc.

Shattuck Labs, Inc.

🇺🇸STTK•NASDAQ

Shattuck Labs, Inc.

🇺🇸STTK•NASDAQ
Market cap
$560.31M
Sentiment

Your view on STTK

Mkt Cap
$560.31M
Sentiment
Your view
STTK
Shattuck Labs, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
STTK
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Shattuck Labs, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Taylor H. Schreiber
Headquarters
500 West 5th Street, Austin, TX, US
Industry
Biotechnology
Sector
Healthcare
CEO
Taylor H. Schreiber
Headquarters
500 West 5th Street, Austin, TX, US
Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Shattuck Labs, Inc., and the rating behind it. STTK last traded at $6.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Shattuck Labs, Inc.. Starting points for Shattuck Labs, Inc.: EPS -$0.41, beta 1.10 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Shattuck Labs, Inc.. Shattuck Labs, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Shattuck Labs, Inc.. Trailing twelve-month EPS for Shattuck Labs, Inc. stands at -$0.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Shattuck Labs, Inc.. Shattuck Labs, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Shattuck Labs, Inc. valued side by side against its closest peers. Shattuck Labs, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Shattuck Labs, Inc., and how their positions are changing. At a $560.3M market value, institutional positions materially move Shattuck Labs, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Shattuck Labs, Inc. executives and directors. Shares of Shattuck Labs, Inc. have traded between $0.69 and $2.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Shattuck Labs, Inc.. Shattuck Labs, Inc. is a $560.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Shattuck Labs, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Shattuck Labs, Inc.. Coverage tracks Shattuck Labs, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ARTV — Artiva Biotherapeutics, Inc.
  • CNTB — Connect Biopharma Holdings Limited
  • CNTX — Context Therapeutics Inc.
  • IFRX — InflaRx N.V.
  • IMA — ImageneBio Inc
  • KLRS — Kalaris Therapeutics Inc
  • MGX — Metagenomi, Inc. Common Stock
  • OVID — Ovid Therapeutics Inc.

More Biotechnology companies

  • LONA — LeonaBio, Inc.
  • LPCN — Lipocine Inc.
  • LRMR — Larimar Therapeutics, Inc.
  • LSTA — Lisata Therapeutics, Inc.
  • LTRN — Lantern Pharma Inc.
  • LVCLF — Algorae Pharmaceuticals Limited
  • LXEO — Lexeo Therapeutics, Inc. Common Stock
  • LXRX — Lexicon Pharmaceuticals, Inc.
  • LYEL — Lyell Immunopharma, Inc.
  • LYRA — Lyra Therapeutics, Inc.
  • LZAGF — Lonza Group AG
  • LZAGY — Lonza Group AG

ETFs holding Shattuck Labs, Inc.

  • IWC — iShares Micro-Cap ETF (0.09%)
  • TNXT — T. Rowe Price Innovation Leaders ETF (0.07%)
  • FSEG — Fidelity Enhanced Small Cap Growth ETF (0.07%)
  • TXS — Texas Capital Texas Equity Index ETF (0.07%)
  • GSSC — Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (0.05%)
  • FSEV — Fidelity Enhanced Small Cap Value ETF (0.05%)
  • FESM — FIDELITY ENHANCED SMALL CAP ETF (0.04%)
  • VTWG — Vanguard Russell 2000 Growth ETF (0.02%)

News

Latest Market News